- Rakovina Therapeutics Inc. (RKV) is receiving funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) and MITACS
- Funding from NRC IRAP will support the development of new research infrastructure
- MITACS funding will support expanded staffing to enable these developments
- Rakovina is focused on the development of new cancer treatments based on novel DNA-damage response technologies
- Rakovina Therapeutics Inc. (RKV) is unchanged trading at $0.20 per share as of 11:36 a.m. EST
Rakovina Therapeutics Inc. (RKV) is receiving funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) and MITACS.
NRC IRAP is giving $56,803 and MITACS is donating $63,750.
Funding from NRC IRAP will support the development of new research infrastructure for screening and optimization of potential drug candidates.
It will be used with Rakovina Therapeutics’ portfolio of novel DNA-damage response inhibitors.
MITACS funding will support expanded staffing to enable these developments.
Proffesor Mads Daugaard, Rakovina Therapeutics’ president and chief scientific officer, stated
“This non-dilutive funding allows us to expand and accelerate our efforts to advance the development of innovative cancer treatments with the potential to improve patient outcomes across multiple tumor types.”
This follows last month’s announcement regarding Rakovina joining a three-year research program for developing treatments for aggressive bone and soft tissue cancer.
It was funded by St. Baldrick’s Foundation Martha’s BEST Grant for All for a total of $1.3 million.
MITACS is a national non-profit organization that connects industry and academia to further research and helps address the needs of small to medium-sized enterprises.
Rakovina is focused on the development of new cancer treatments based on novel DNA-damage response technologies.
Rakovina Therapeutics Inc. (RKV) is unchanged trading at $0.20 per share as of 11:36 a.m. EST.
